332386-74-0

Basic information

• Product Name: 2H-1-Benzopyran-3-ol, 3,4-dihydro-5,7-bis(phenylmethoxy)-2-[3,4,5-tris(phenylmethoxy)phenyl]- , (2R,3R)-
• CAS NO: 332386-74-0
• Molecular Formula: C50H44O7
• Molecular Weight: 756.895
• Mol File: 332386-74-0.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: 2H-1-Benzopyran-3-ol, 3,4-dihydro-5,7-bis(phenylmethoxy)-2-[3,4,5-tris(phenylmethoxy)phenyl]- , (2R,3R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-1-Benzopyran-3-ol, 3,4-dihydro-5,7-bis(phenylmethoxy)-2-[3,4,5-tris(phenylmethoxy)phenyl]- , (2R,3R)-(332386-74-0)
• EPA Substance Registry System: 2H-1-Benzopyran-3-ol, 3,4-dihydro-5,7-bis(phenylmethoxy)-2-[3,4,5-tris(phenylmethoxy)phenyl]- , (2R,3R)-(332386-74-0)

Safety Data

• Hazardous Substances Data: 332386-74-0(Hazardous Substances Data)

Upstream product

• 332386-67-1 ethyl (E)-3,4,5-tris(benzyloxy)cinnamate 
• 100-39-0 benzyl bromide 
• 970-73-0 epigallocatechin 
• 1187052-74-9 C₅₆H₅₈O₇Si 
• 1042159-87-4 3-O-acetyl-3′,4′,5,5′,7-penta-O-benzyl-(?)-epigallocatechin 
• 332386-77-3 (-)-(2R,3R)-cis-5,7-bis(benzyloxy)-2-[3,4,5-tris(benzyloxy)phenyl]chroman-3-yl 3,4,5-tris(benzyloxy)benzoate 
• 942122-64-7 (1S,2S)-3-[2,4-bis(benzyloxy)-6-(tert-butyldimethylsilyloxy)phenyl]-1-[3,4,5-tris(benzyloxy)phenyl]propane-1,2-diol 
• 332386-55-7 (E)-3-[2,4-bis(benzyloxy)-6-(tert-butyldimethylsilyloxy)phenyl]-1-[3,4,5-tris(benzyloxy)phenyl]propene 
• 332386-60-4 (-)-(1S,2S)-3-[2,4-bis(benzyloxy)-6-hydroxyphenyl]-1-[3,4,5-tris(benzyloxy)phenyl]propane-1,2-diol 
• 332386-71-7 (-)-(2R,3S)-trans-5,7-bis(benzyloxy)-2-[3,4,5-tris(benzyloxy)phenyl]chroman-3-ol 
• 332386-61-5 (E)-3-[2,4-bis(benzyloxy)-6-hydroxyphenyl]-1-[3,4,5-tris(benzyloxy)phenyl]-propene 
• 332386-68-2 (E)-3-[3,4,5-tris(benzyloxy)phenyl]prop-2-en-1-ol 
• 70424-94-1 methyl 3,4,5-tris(benzyloxy)benzoate 
• 79831-88-2 3,4,5-tribenzyloxybenzyl alcohol 

Downstream Products

• 332386-77-3 (-)-(2R,3R)-cis-5,7-bis(benzyloxy)-2-[3,4,5-tris(benzyloxy)phenyl]chroman-3-yl 3,4,5-tris(benzyloxy)benzoate 
• 901125-31-3 (-)-(2R,3R)-cis-5,7-bis(benzyloxy)-2-[3',4',5'-tris(benzyloxy)-phenyl]chroman-3-yl 3'',4''-dibenzyloxy-5''-methoxybenzoate 
• 901125-32-4 (-)-(2R,3R)-cis-5,7-bis(benzyloxy)-2-[3',4',5'-tris(benzyloxy)-phenyl]chroman-3-yl 3'',5''-dibenzyloxy-4''-methoxybenzoate 
• 2596-50-1 (-)-epigallocathechin gallate 
• 947238-00-8 (-)-(2R,3R)-5,7-bis(benzyloxy)-2-[3,4,5-tris(benzyloxy)-phenyl]chroman-3-yl 4-(benzyloxy)benzoate 
• 1042159-88-5 (2R,3R)-5,7-bis(benzyloxy)-2-(3,4,5-tris(benzyloxy)phenyl)chroman-3-yl 3-acetoxybenzoate 
• 970-73-0 epigallocatechin 
• 1338809-96-3 (2R,3R)-5,7-bis(benzyloxy)-2-(3,4,5-tris(benzyl-oxy)phenyl)chroman-3-yl 4-(methoxymethoxy)benzoate 
• 1338809-97-4 (2R,3R)-5,7-bis(benzyloxy)-2-(3,4,5-tris(benzyl-oxy)phenyl)chroman-3-yl 3-(methoxymethoxy)benzoate 
• 1338809-98-5 (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-chroman-3-yl 4-(methoxymethoxy)benzoate 
• 1338809-99-6 (2R,3R)-5,7-diacetoxy-2-(3,4,5-triacetoxyphenyl)-chroman-3-yl 4-(methoxymethoxy)benzoate 
• 1338810-01-7 (2R,3R)-5,7-diacetoxy-2-(3,4,5-triacetoxyphenyl)-chroman-3-yl 4-(hydroxy)benzoate 
• 1338810-03-9 (2R,3R)-5,7-diacetoxy-2-(3,4,5-triacetoxyphenyl)-chroman-3-yl 4-(dibenzyloxyphosphoryloxy)benzoate 
• 1338809-86-1 (2R,3R)-5,7-diacetoxy-2-(3,4,5-triacetoxyphenyl)-chroman-3-yl 4-(phosphoryloxy)benzoate 

Relevant articles and documents

Design and synthesis of epigallocatechin (EGC) analogs selective to inhibit α-amylase over α-glucosidases via the incorporation of caffeine acid and its derivatives

Natural products are a promising and underappreciated reservoir for the preferred chemical scaffolds in the search of antidiabetic drugs. In this study twenty-one EGC-based derivatives selective to inhibit human pancreatic α-amylase (HPA), the enzyme at t

Molecular Mechanism by Which Tea Catechins Decrease the Micellar Solubility of Cholesterol

Tea polyphenols lower the levels of cholesterol in the blood by decreasing the cholesterol micellar solubility. To clarify this mechanism, the interactions between taurocholic acid and (-)-epigallocatechin gallate (EGCg) and its derivatives were investigated. 13C NMR studies revealed remarkable chemical-shift changes for the carbonyl carbon atom and the 1″- and 4″-positions in the galloyl moiety. Furthermore, 1H NMR studies using (-)-EGCg derivatives showed that the number of hydroxyl groups on the B ring did not affect these interactions, whereas the carbonyl carbon atom and the aromatic ring of the galloyl moiety had remarkable effects. The configuration at the 2- and 3-positions of the catechin also influenced these interactions, with the trans-configuration resulting in stronger inhibition activity than the cis-configuration. Additionally, a 1:1 component ratio for the catechin-taurocholic acid complex was determined by electrospray ionization-mass spectrometry. These molecular mechanisms contribute to the development of cholesterol-absorption inhibitors.

NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF LEIOMYOMA

This invention provides novel compositions and methods for the treatment of leiomyoma. In some other aspects, this invention provides novel compositions and methods comprising prodrugs of (-)-epigallocatechin-3-gallate (EGCG) and prodrugs of (-)-EGCG anal